However, due to danugliprons potential for drug-induced liver damage, 2025 Pfizer has announced that it is discontinuing development ( in vitro and in vivo with a reduced risk of drug-drug interactions and is undergoing phase 2 clinical trials
Additional insurance requirements may include participation in a structured weight loss program, nutrition counseling, exercise programs, behavioral health interventions, or regular follow-up visits
Loss of growth hormonemediated signal transducer and activator of transcription 5 (STAT5) signaling in mice results in insulin sensitivity with obesity
SURPASS-4, a multicenter open-label RCT comparing treatment with tirzepatide and insulin glargine in T2D patients at increased CV risk for a median of 85 weeks, was the only study in the SURPASS program to include the change from baseline in eGFR and UACR and occurrence of eGFR decline of at least 40%, renal death, progression to end-stage kidney disease or new-onset MA among the prespecified analyses [48]
However, this represents a minority of cases